A Label Change Does Not Replace Individual Risk Review Why the 2025 FDA shift changes the conversation around menopausal hormone therapy without removing the need for careful screening How timing, formulation, and route…
Read More
When menopause symptoms return after cancer treatment, the path forward needs nuance Older hormone studies still shape today’s caution, even as newer expert consensus pushes for more individualized risk review. Non-hormonal care and…
Read More
Weight-loss care is expanding well beyond the incretin pathway FGF21 and GDF15 analogs are drawing attention because they target metabolism, appetite signaling, and liver fat through different biologic routes. This matters most for…
Read More
When fat loss stops being just an appetite story Why brown fat and thermogenesis matter when calorie burn feels unusually stubborn. How metabolism-focused strategies differ from older, appetite-only weight loss approaches. Which next…
Read More
When Hormone Dosing Needs a Closer Look Helpful context for readers dealing with hot flashes, sleep disruption, mood variability, or dose-sensitive symptom swings. A clearer bridge between today’s lab-based hormone care and the…
Read More
Why this research matters before symptoms fully take over Useful context for women watching cycle changes, sleep disruption, metabolic shifts, or other signs that perimenopause may be changing the pace of daily life.…
Read More
Where brain-based weight maintenance may fit Useful for readers looking at appetite rebound, post-GLP-1 maintenance, or weight regain after early success. Clarifies how CNS-directed therapies differ from gut-based medications and why tolerability can…
Read More
The future may be physiologic, but today’s hormone decisions still matter Bioengineered ovaries are an emerging research path, not a current treatment option. The core reader question usually comes down to whether current…
Read More
Weight loss should protect more than the number on the scale The real question is not only how much weight comes off, but how much strength-supporting tissue stays in place. Combination therapies like…
Read More
A one-shot obesity therapy sounds compelling, but the real question is what can be acted on now RJVA-002 is still preclinical, so it belongs to the research pipeline rather than today’s treatment menu.…
Read More